

FIRST LIGHT 25 January 2024

#### RESEARCH

HITACHI ENERGY | TARGET: Rs 4,200 | -26% | SELL

In-line quarter but valuations overdone; cut to SELL

**BOB ECONOMICS RESEARCH | FY25 BUDGET PREVIEW** 

Focus to remain on consolidation

KOTAK MAHINDRA BANK | TARGET: Rs 2,100 | +17% | BUY

NIM intact QoQ; higher provisions dull profit

AXIS BANK | TARGET: Rs 1,252 | +18% | BUY

Profits subdued despite strong business growth

HAVELLS INDIA | TARGET: Rs 1,600 | +22% | BUY

Slow quarter but summer could bring cheer; maintain BUY

KEI INDUSTRIES | TARGET: Rs 3,120 | -6% | HOLD

Decent quarter; maintain HOLD

JK CEMENT | TARGET: Rs 4,121 | -0% | HOLD

Healthy performance but priced in

GLENMARK LIFE SCIENCES | TARGET: Rs 765 | -4% | HOLD

Strong margins make up for subdued revenue growth

# **SUMMARY**

### **HITACHI ENERGY**

- Q3 EBITDA margin rose 150bps YoY to 5.3% as chip constraints eased, leading to 5x jump in PAT off a low base
- Management retains guidance of double-digit margins by end-FY25 led by HVDC, rail and export orders
- Stock has rallied sharply by 70% in FY24 YTD and current P/E of 65x on Dec'25E looks overstated – cut from HOLD to SELL

Click here for the full report.

**Daily macro indicators** 

| Indicator                 | 22-Jan    | 23-Jan  | Chg (%)        |
|---------------------------|-----------|---------|----------------|
| US 10Y<br>yield (%)       | 4.11      | 4.13    | 2bps           |
| India 10Y<br>yield (%)    | 7.18      | 7.18    | 0bps           |
| USD/INR                   | 83.07     | 83.16   | (0.1)          |
| Brent Crude<br>(US\$/bbl) | 80.1      | 79.6    | (0.6)          |
| Dow                       | 38,002    | 37,905  | (0.3)          |
| Hang Seng                 | 14,961    | 15,354  | 2.6            |
| Sensex                    | 71,424    | 70,371  | (1.5)          |
| India FII<br>(US\$ mn)    | 18-Jan    | 19-Jan  | Chg<br>(\$ mn) |
| FII-D                     | 144.1     | 70.4    | (73.7)         |
| FII-E                     | (1,106.1) | (427.5) | 678.6          |

Source: Bank of Baroda Economics Research

**BOBCAPS** Research

research@bobcaps.in





#### INDIA ECONOMICS: FY25 BUDGET PREVIEW

With 2024-25 budget being an interim one, government will focus on maintaining continuity of policies, while committing itself to the path of fiscal consolidation. We expect centre to achieve its fiscal deficit target of 5.9% in FY24, with risks titled to the upside. These risks emerge from: lower than anticipated nominal GDP growth, and higher than budgeted expenditure. From these levels, government is expected to reduce deficit target by ~50bps in FY25BE, thus targeting 5.4-5.5% range in our base case scenario. In the wake of weak monsoon, and subdued Rabi sowing, budget will focus on steering rural growth. For this, enhanced spending on MGNREGA, PM KISAN, and PMAY can be expected. Driving investment growth will be another focus area for the government. We thus expect Rs 1.5-2 lakh crore incremental increase in capex for the next year. Markets will also keep a watchful eye on government's borrowing program, which is anticipated to increase only marginally next year.

Click here for the full report.

### **KOTAK MAHINDRA BANK**

- Business growth held strong in Q3, but treasury losses and higher provisions weighed on PAT (-6% QoQ)
- Reported NIM was stable sequentially at 5.2%, asset quality healthy with controlled slippages, and credit cost flat ex-AIF provision
- TP revised to Rs 2,100 from Rs 2,007 as we now value the stock at 2.5x on FY26E ABV (vs. 2.7x on FY25E)

Click here for the full report.

### **AXIS BANK**

- NII growth subdued at 9% YoY despite credit/deposit growth of 22%/18%, due to a high cost of funds
- Reported NIM declined 10bps QoQ to 4%; higher opex and provisions slowed PAT growth to ~3% YoY and QoQ
- Maintain BUY with revised TP of Rs 1,252 (vs. Rs 1,155), set at 1.7x FY26E ABV (vs. 1.9x on FY25E)

Click here for the full report.

# **HAVELLS INDIA**

- Q3 revenue grew just 7% YoY on subdued demand; high A&P spend hurt margins even as Lloyd's cash burn continued
- Management anticipates a better Q4 on summer demand for fans and ACs;
  infrastructure spends to drive cables and switchgears
- We cut FY24-FY26 EPS by 4-8% post results; on rollover, our TP stays at Rs 1,600 – maintain BUY

Click here for the full report.



### **KEI INDUSTRIES**

- Q3 revenue grew 16% YoY with 30bps EBITDA margin expansion; order book up 11% on strong domestic demand
- FY24 guidance of 16-17% revenue growth and 11% EBITDA margin maintained; annual capex to continue at Rs 5bn-6bn
- We raise FY24-FY26 EPS 4-8% and roll to a 33x P/E multiple on Dec'25E (vs. 28x) for a new TP of Rs 3,120 (vs. Rs 2,400); retain HOLD

Click here for the full report.

### **JK CEMENT**

- Q3 revenue grew 22% YoY to Rs 27.8bn as new grey cement capacities aided
  17% volume growth and realisation improved 5%
- EBITDA spiked to Rs 6.1bn with healthy margins of 21.8%, partly supported by Rs 1.2bn inventory adjustment
- TP revised to Rs 4,121 (vs. Rs 3,578) as we roll valuations over to FY26E;
  maintain HOLD

Click here for the full report.

## **GLENMARK LIFE SCIENCES**

- Q3 revenue growth a miss at 6% YoY but robust 670bps expansion in gross margin helped mitigate the impact on bottomline
- EBITDA/PAT grew 19%/13% YoY on higher margins in line with consensus
- Our DCF-based TP stands revised to Rs 765 (vs. Rs 620) as we raise FY24-FY26 EPS 4-8%; maintain HOLD as valuations look fair post rally

Click here for the full report.



SELL TP: Rs 4,200 | ¥ 26%

**HITACHI ENERGY** 

Capital Goods

24 January 2024

### In-line quarter but valuations overdone; cut to SELL

- Q3 EBITDA margin rose 150bps YoY to 5.3% as chip constraints eased, leading to 5x jump in PAT off a low base
- Management retains guidance of double-digit margins by end-FY25 led by HVDC, rail and export orders
- Stock has rallied sharply by 70% in FY24 YTD and current P/E of 65x on Dec'25E looks overstated – cut from HOLD to SELL

Vinod Chari | Arshia Khosla Swati Jhunjhunwala research@bobcaps.in

**Improved YoY numbers**: Hitachi's Q3FY24 revenue grew 23% YoY to Rs 12.7bn, and the easing chip shortage aided 150bps YoY improvement in EBITDA margin to 5.3% (flat QoQ). PAT came in at Rs 230mn compared to Rs 46mn on a YoY basis.

**Chip constraints reduce:** The company has been plagued by chip shortages over the past few quarters, but management indicated that supply chain constraints have receded in Q3 and it is now equipped to better manage the same.

**Good order inflow mix:** Q3 order intake was flat at 1% YoY to Rs 12.3bn with 25% export share, taking the backlog to Rs 75.5bn which signifies 22 months of revenue visibility. This compares well will the Rs 75.9bn backlog in Q2FY24 and Rs 70.7bn in FY23. Transmission projects from multiple state utilities, renewable orders, Chennai metro rail, data centre and hydropower orders, along with exports to Africa, the Middle East and Europe drove the inflows. This mix of export and service orders augurs well for margins in coming quarters.

**Guidance retained:** Management maintained its guidance of reaching a double-digit EBITDA margin run-rate by the close of FY25.

Valuations overstated; cut to SELL: We remain positive on Hitachi's order prospects but lower our FY24/FY25/FY26 EPS estimates by 35%/11%/9% to reflect the below-expected 9MFY24 performance. Our TP remains at Rs 4,200 as we roll valuations forward to Dec'25E and reset to a 48x target P/E from 45x earlier to maintain our 50% valuation premium to the stock's three-year average. The stock has run up 27% since our last quarterly update of 6 Nov 2023, propelling valuations to 65x Dec'25E EPS, which we believe look overdone given the tepid margin performance so far. We downgrade the stock from HOLD to SELL and await a better entry point.

#### **Key changes**

| <br>   |        |  |
|--------|--------|--|
| Target | Rating |  |
| < ▶    | ▼      |  |

| Ticker/Price     | POWERIND IN/Rs 5,673 |
|------------------|----------------------|
| Market cap       | US\$ 2.9bn           |
| Free float       | 25%                  |
| 3M ADV           | US\$ 2.7mn           |
| 52wk high/low    | Rs 6,280/Rs 2,906    |
| Promoter/FPI/DII | 75%/5%/2%            |
|                  |                      |

Source: NSE | Price as of 24 Jan 2024 | POWERIND = Hitachi

#### **Key financials**

| Y/E 31 Mar              | FY23A  | FY24E  | FY25E  |
|-------------------------|--------|--------|--------|
| Total revenue (Rs mn)   | 44,685 | 51,160 | 61,520 |
| EBITDA (Rs mn)          | 2,359  | 3,029  | 5,487  |
| Adj. net profit (Rs mn) | 939    | 1,370  | 3,138  |
| Adj. EPS (Rs)           | 22.2   | 32.3   | 74.0   |
| Consensus EPS (Rs)      | 22.2   | 58.0   | 95.0   |
| Adj. ROAE (%)           | 8.0    | 10.7   | 21.1   |
| Adj. P/E (x)            | 256.1  | 175.6  | 76.6   |
| EV/EBITDA (x)           | 101.7  | 79.0   | 43.9   |
| Adj. EPS growth (%)     | (44.0) | 45.9   | 129.1  |

Source: Company, Bloomberg, BOBCAPS Research

### Stock performance







### **FY25 BUDGET PREVIEW**

24 January 2024

### Focus to remain on consolidation

With 2024-25 budget being an interim one, government will focus on maintaining continuity of policies, while committing itself to the path of fiscal consolidation. We expect centre to achieve its fiscal deficit target of 5.9% in FY24, with risks titled to the upside. These risks emerge from: lower than anticipated nominal GDP growth, and higher than budgeted expenditure. From these levels, government is expected to reduce deficit target by ~50bps in FY25BE, thus targeting 5.4-5.5% range in our base case scenario. In the wake of weak monsoon, and subdued Rabi sowing, budget will focus on steering rural growth. For this, enhanced spending on MGNREGA, PM KISAN, and PMAY can be expected. Driving investment growth will be another focus area for the government. We thus expect Rs 1.5-2 lakh crore incremental increase in capex for the next year. Markets will also keep a watchful eye on government's borrowing program, which is anticipated to increase only marginally next year.

Sonal Badhan Economist

### **Expectations from FY25 Budget**

Since the latest budget presentation for 2024-25 (FY25) will be an interim budget before the General Elections of 2024, no significant announcements are expected to be made. Government will try maintaining continuity of policies and schemes already announced, while sticking to its path of fiscal consolidation. For the central government to reach its target of 4.5% fiscal deficit target by FY26, it is likely to announce ~50bps reduction in fiscal deficit target for FY25. Challenges that may emerge include: normalisation of nominal GDP and hence receipt growth. On the other hand, quality of expenditure is unlikely to be compromised upon for two reasons—one, to crowd in private investments by boosting government capex (RBI monthly bulletin reaffirms this trend), two, to support growth and maintain continuity of key social schemes. We give here our expectations, which have been placed forth keeping in mind the practical side of fiscal space that will be available.

# Key themes: Steering rural growth and investment

Given a weaker than expected monsoon in FY24 and muted Rabi sowing (+0.2% as of 19 Jan 2024), government through its budget will aim to give rural growth a boost. Government capex is also expected to maintain a healthy pace of growth to give nudge to private investment. To support these agendas, government may:

- Increase the budget allocation for PM Kisan Samman Nidhi (PM-KISAN) scheme from Rs 60,000 crore in FY24BE to ~Rs 70-75,000 crore in FY25.
- Increase the budget allocation for MG-NREGA scheme from Rs 60,000 crore in FY24BE to ~Rs 80-85,000 crore in FY25.
- Provisions under affordable housing (rural and urban) are expected to touch
  Rs 1 lakh crore from ~Rs 80,000 crore as FY24BE.





BUY TP: Rs 2,100 | *∧* 17%

# KOTAK MAHINDRA BANK

Banking

24 January 2024

# NIM intact QoQ; higher provisions dull profits

- Business growth held strong in Q3, but treasury losses and higher provisions weighed on PAT (-6% QoQ)
- Reported NIM was stable sequentially at 5.2%, asset quality healthy with controlled slippages, and credit cost flat ex-AIF provision
- TP revised to Rs 2,100 from Rs 2,007 as we now value the stock at 2.5x on FY26E ABV (vs. 2.7x on FY25E)

Ajit Agrawal research@bobcaps.in

Mixed sequential performance: KMB posted modest PAT of Rs 30.1bn (+8% YoY/-6% QoQ) in Q3FY24 on account of a one-off provision of Rs 1.9bn towards exposure to AIFs along with a treasury loss of Rs 1.7bn. However, NII grew at a healthy 16% YoY (+4% QoQ) on the back of strong business growth, wherein advances rose 16% YoY (+3% QoQ) and deposits increased 19% YoY (+ 2% QoQ). Other income was muted once again (+9% YoY/-1% QoQ) due to treasury losses along with elevated opex on a sequential basis as the bank continued to invest in employee and network expansion. The C/I ratio increased by 194bps QoQ to 48.4%.

Robust business growth: Deposit growth outpaced loan growth driven by term deposits. The 'ActivMoney' product grew at a strong 23% QoQ, helping the bank fund credit demand. Healthy credit growth was fuelled by the unsecured retail book which contributed 11.6% of loans vs. 11% in Q2 – in line with the bank's strategy of taking unsecured share to the mid-teens. The corporate book grew 20% YoY while SME loan growth was modest at 11.5%. In the retail book, commercial vehicle, personal and consumer durable loans along with credit cards and the MFI book outperformed. We broadly retain FY24/FY25 loan estimates while cutting deposit estimates by 2%/3%.

**NIM flat sequentially:** Reported NIM at 5.2% was flat QoQ supported by an increased share of high-yielding assets which offset the higher cost of deposits. Management expects deposit repricing to continue for the next 1-2 quarters but believes a favourable loan mix would enable it to maintain margins at current levels.

**Asset quality stable, credit cost dips:** Controlled slippages led to flat GNPA/NNPA of 1.7%/0.3% while PCR improved 150bps QoQ. Reported credit cost (ex-AIF provision) improved to 40bps from 47bps in Q2. KMB is well capitalised at 21.3% CAR.

**Maintain BUY:** Given strong growth in the high-yielding unsecured portfolio, we raise our FY24/FY25 NII estimates by 2%/4%, leading to a 2%/5% hike in PAT. We introduce FY26 forecasts and roll valuations forward, leading to a revised SOTP-based TP of Rs 2,100 from Rs 2,007, set at 2.5x FY26E ABV (vs. 2.7x on FY25E) using the Gordon Growth Model. This includes Rs 659/sh as the value of subsidiaries.

### Key changes

| Target   | Rating     |
|----------|------------|
| <b>A</b> | <b>∢</b> ▶ |

| Ticker/Price     | KMB IN/Rs 1,789   |
|------------------|-------------------|
| Market cap       | US\$ 46.7bn       |
| Free float       | 74%               |
| 3M ADV           | US\$ 84.7mn       |
| 52wk high/low    | Rs 2,064/Rs 1,644 |
| Promoter/FPI/DII | 26%/40%/21%       |


Source: NSE | Price as of 24 Jan 2024

#### **Key financials**

| Y/E 31 Mar              | FY23A  | FY24E  | FY25E  |
|-------------------------|--------|--------|--------|
| Net interest income     | 21,552 | 25,866 | 30,703 |
| NII growth (%)          | 28.1   | 20.0   | 18.7   |
| Adj. net profit (Rs mn) | 10,939 | 12,925 | 15,031 |
| EPS (Rs)                | 55.1   | 60.3   | 70.1   |
| Consensus EPS (Rs)      | 55.1   | 64.9   | 73.1   |
| P/E (x)                 | 32.5   | 29.7   | 25.5   |
| P/BV (x)                | 4.3    | 4.0    | 3.5    |
| ROA (%)                 | 2.8    | 2.4    | 2.4    |
| ROE (%)                 | 17.8   | 14.4   | 14.5   |

Source: Company, Bloomberg, BOBCAPS Research

### Stock performance







BUY TP: Rs 1,252 | ▲ 18%

**AXIS BANK** 

Banking

24 January 2024

# Profits subdued despite strong business growth

- NII growth subdued at 9% YoY despite credit/deposit growth of 22%/18%, due to a high cost of funds
- Reported NIM declined 10bps QoQ to 4%; higher opex and provisions slowed PAT growth to ~3% YoY and QoQ
- Maintain BUY with revised TP of Rs 1,252 (vs. Rs 1,155), set at 1.7x
  FY26E ABV (vs. 1.9x on FY25E)

Ajit Agrawal research@bobcaps.in

**Robust business growth:** AXSB's advances increased 22% YoY (+4% QoQ) during Q3FY24 on the back of robust growth in the retail segment at 27% YoY while SME loans grew 22% YoY. Corporate loans saw a modest 4% uptick. Retail growth was mainly fuelled by rural lending (+34%), LAP (+32%), personal loans (+28%) and small business banking (+40%). Deposits increased 18.5% YoY (+5% QoQ) driven by term deposits, which led to a 240bps YoY drop in CASA ratio to 42% (still amongst the best in industry). We raise our loan estimates by 3% each in FY24/FY25 and project a credit/deposit CAGR of 17%/19% over FY23-FY26.

**NIM down QoQ, opex rises:** Reported NIM declined 10bps sequentially to 4% on a higher cost of deposits. The bank expects a further rise in deposit cost for the next 1-2 quarters, though an increasing share of high-yielding assets may offset some of the pressure. AXSB indicated that NIM is likely to hold at current levels with some downward bias. Other income grew 10% QoQ backed by trading gains and a better performance from DCM business. Opex increased 36% YoY on higher volumes.

**Asset quality steady:** Despite an increase in slippages to Rs 37.1bn from Rs 32.5bn in Q2, GNPA improved to 1.6% due to the upgrade of a large restructured corporate account. NNPA was flat at 0.4% and PCR declined 165bps QoQ to 77.8%. Credit cost (ex-AIF provision of Rs 1.8bn) was flat at 38bps.

**Adequately capitalised for growth:** CET1 stood at 13.7% (CAR at 16.6%), and AXSB is confident of funding credit growth internally (added 39bps of CET1 in 9MFY24 despite using 70bps to meet regulatory changes).

**Maintain BUY:** AXSB continues to deliver a healthy performance backed by a sustained focus on growth, healthy portfolio mix, stable asset quality and steady investment in network expansion. We introduce FY26 forecasts and roll valuations forward, translating to a new SOTP-based TP of Rs 1,252 from Rs 1,155, set at 1.7x FY26E ABV (vs. 1.9x on FY25E) using the Gordon Growth Model. Our target includes Rs 133/sh as the value of subsidiaries.

### **Key changes**

| Target   | Rating |
|----------|--------|
| <b>A</b> | <▶     |

| Ticker/Price     | AXSB IN/Rs 1,059 |
|------------------|------------------|
| Market cap       | US\$ 39.8bn      |
| Free float       | 92%              |
| 3M ADV           | US\$ 115.6mn     |
| 52wk high/low    | Rs 1,152/Rs 814  |
| Promoter/FPI/DII | 8%/55%/29%       |
|                  |                  |

Source: NSE | Price as of 24 Jan 2024

#### **Key financials**

| Y/E 31 Mar              | FY23A   | FY24E   | FY25E   |
|-------------------------|---------|---------|---------|
| Net interest income     | 429,457 | 499,177 | 584,054 |
| NII growth (%)          | 29.6    | 16.2    | 17.0    |
| Adj. net profit (Rs mn) | 95,797  | 241,498 | 277,785 |
| EPS (Rs)                | 31.2    | 78.4    | 90.1    |
| Consensus EPS (Rs)      | 31.2    | 77.8    | 87.5    |
| P/E (x)                 | 34.0    | 13.5    | 11.8    |
| P/BV (x)                | 2.6     | 2.2     | 1.9     |
| ROA (%)                 | 8.0     | 1.7     | 1.7     |
| ROE (%)                 | 8.0     | 17.8    | 17.3    |

Source: Company, Bloomberg, BOBCAPS Research

### Stock performance







BUY TP: Rs 1,600 | ♠ 22%

**HAVELLS INDIA** 

Consumer Durables

24 January 2024

# Slow quarter but summer could bring cheer; maintain BUY

- Q3 revenue grew just 7% YoY on subdued demand; high A&P spend hurt margins even as Lloyd's cash burn continued
- Management anticipates a better Q4 on summer demand for fans and ACs; infrastructure spends to drive cables and switchgears
- We cut FY24-FY26 EPS by 4-8% post results; on rollover, our TP stays at Rs 1,600 – maintain BUY

Vinod Chari | Swati Jhunjhunwala Arshia Khosla research@bobcaps.in

**Slow quarter:** HAVL posted soft topline growth of 6.9% YoY to Rs 44bn as consumer demand remained subdued. Gross margin improved by 30bps YoY to 33.3% but increasing promotional expenditure during the festive season caused EBITDA margin to contract 50bps to 9.8%. A&P spend rose to ~4% of sales as against the usual rate of ~3%.

Cables & wires lead growth: The cables & wires business grew 11.4% YoY on the back of infrastructure demand and remains HAVL's best performing segment. However, the company still lags peer POLYCAB, which saw 18% topline growth, as well as KEII, which grew 14% in Q3. HAVL's lighting segment outperformed peers, growing at 2.4% YoY amid continued price erosion, largely led by professional lighting. The electrical consumer durables (ECD) business was flattish YoY due to a high base quarter that saw fan inventory liquidation due to energy norm changes.

**Losses at Lloyd continue:** Lloyd posted an EBIT loss of Rs 646mn in Q3, with topline growth remaining in single digits for the quarter at 8% YoY. HAVL expects the next couple of quarters to be stronger with the onset of the summer season.

**Management optimistic on Q4:** HAVL indicated a positive demand outlook for the upcoming summer season and expects to earn better margins in Q4FY24 compared to those seen in Q3, as it expects a pickup in demand for fans and air conditioners. Cables, wires and switches are also expected to do well on the back of rising infrastructure spending.

**Maintain BUY:** We remain positive on HAVL's medium-term performance given its strong presence in the consumer durables sector and improving industry dynamics. Incorporating the slower quarterly performance than anticipated, we lower our FY24/FY25/FY26 EPS estimates by 8%/4%/4%. On rolling valuations forward to Dec'25E, our TP remains at Rs 1,600, based on an unchanged 53x P/E multiple which is in line with the stock's 3Y average. BUY.

### **Key changes**

| Target Rating        | 1 |
|----------------------|---|
| <b>4 &gt; 4 &gt;</b> |   |

| Ticker/Price     | HAVL IN/Rs 1,313  |
|------------------|-------------------|
| Market cap       | US\$ 10.0bn       |
| Free float       | 41%               |
| 3M ADV           | US\$ 11.4mn       |
| 52wk high/low    | Rs 1,472/Rs 1,132 |
| Promoter/FPI/DII | 60%/23%/10%       |

Source: NSE | Price as of 23 Jan 2024

#### **Key financials**

| FY23A    | FY24E  | FY25E  |
|----------|--|--|
| 1,69,107 | 1,83,659   | 2,09,084   |
| 15,991   | 17,428   | 22,768   |
| 10,717   | 12,142   | 15,809   |
| 17.1     | 19.4   | 25.2   |
| 17.1     | 21.2   | 27.2   |
| 17.0     | 17.4   | 20.2   |
| 76.8     | 67.8   | 52.0   |
| 51.4     | 47.2   | 36.1   |
| (10.4)   | 13.3   | 30.2   |
|          | 1,69,107<br>15,991<br>10,717<br>17.1<br>17.1<br>17.0<br>76.8<br>51.4 | 1,69,107 1,83,659<br>15,991 17,428<br>10,717 12,142<br>17.1 19.4<br>17.1 21.2<br>17.0 17.4<br>76.8 67.8<br>51.4 47.2 |

Source: Company, Bloomberg, BOBCAPS Research

### Stock performance







HOLD TP: Rs 3,120 | ∀ 6%

**KEI INDUSTRIES** 

Consumer Durables

24 January 2024

## Decent quarter; maintain HOLD

- Q3 revenue grew 16% YoY with 30bps EBITDA margin expansion; order book up 11% on strong domestic demand
- FY24 guidance of 16-17% revenue growth and 11% EBITDA margin maintained; annual capex to continue at Rs 5bn-6bn
- We raise FY24-FY26 EPS 4-8% and roll to a 33x P/E multiple on Dec'25E (vs. 28x) for a new TP of Rs 3,120 (vs. Rs 2,400); retain HOLD

Vinod Chari | Arshia Khosla Swati Jhunjhunwala research@bobcaps.in

**Decent quarter:** KEII posted Q3FY24 revenue of Rs 20.6bn, an increase of 15.5% YoY and 11.9% on a 4Y CAGR basis. Gross margin expanded 60bps YoY to 23.8% and EBITDA margin increased 30bps YoY to 10.5%. Adj. PAT at Rs 1.5bn grew 17% YoY, making for a 4Y CAGR of 20%. The company's order book moved up 11% YoY and 13.8% QoQ to Rs 38.3bn.

**Cables revenue sound:** Cables business revenue at Rs 18.7bn increased 14.4% YoY, as against 16.8% YoY for POLYCAB and 11.4% for HAVL. Segmental EBIT margin rose 120bps YoY to 10.6%, compared to a flat margin for HAVL at 10.4% and 30bps expansion for POLYCAB to 14%.

**Guidance retained:** Management maintained guidance of 16-17% revenue growth for the next few years and an ~11% EBITDA margin for FY24 and FY25. KEII sees scope for improving margins by a further 50-75bps.

**Tackling a capacity crunch:** In our view, the key reason KEII lags peers is a lack of capacity. During Q3, the company operated at 95% utilisation in cables and 70% in house wires, which affected volume growth. This was partly addressed in Q2FY24 when brownfield expansion for high- and low-tension wires came onstream. The company is incurring further capex to tackle the capacity crunch – it spent Rs 3bn in 9MFY24, with another ~Rs 1.5bn planned for Q4FY24 and Rs 5bn-6bn guided for FY25.

**Demand outlook positive:** Management sees substantial export opportunities and expects domestic demand for wires and cables to sustain on the back of continuing private and public sector capex. Demand from key verticals such as highways, metros, hotels, hospitals and other real estate is gaining traction as well.

**Maintain HOLD:** We raise our FY24-FY26 EPS estimates by 4-8% post Q3 and now value the stock at 33x P/E (vs. 28x earlier) – in line with the sector average and at a 15% discount to POLYCAB. On rolling valuations over to Dec'25E, we arrive at a higher TP of Rs 3,120 (vs. Rs 2,400). However, given the sharp 32% run-up in stock price during the last quarter, we maintain our HOLD rating.

### Key changes

| Target   | Rating |  |
|----------|--------|--|
| <b>A</b> | < ▶    |  |

| Ticker/Price     | KEII IN/Rs 3,315  |
|------------------|-------------------|
| Market cap       | US\$ 3.6bn        |
| Free float       | 61%               |
| 3M ADV           | US\$ 12.5mn       |
| 52wk high/low    | Rs 3,419/Rs 1,508 |
| Promoter/FPI/DII | 37%/27%/20%       |


Source: NSE | Price as of 24 Jan 2024

#### **Key financials**

| FY23A  | FY24E  | FY25E  |
|--------|--|--|
| 69,123 | 80,781   | 94,765   |
| 7,062  | 8,735  | 10,947   |
| 4,773  | 6,001  | 7,409  |
| 52.9   | 66.5   | 82.2   |
| 52.9   | 65.3   | 79.9   |
| 20.2   | 20.9   | 21.1   |
| 62.6   | 49.8   | 40.3   |
| 42.4   | 34.7   | 27.6   |
| 27.0   | 25.7   | 23.5   |
|        | 69,123<br>7,062<br>4,773<br>52.9<br>52.9<br>20.2<br>62.6<br>42.4 | 69,123 80,781<br>7,062 8,735<br>4,773 6,001<br>52.9 66.5<br>52.9 65.3<br>20.2 20.9<br>62.6 49.8<br>42.4 34.7 |

Source: Company, Bloomberg, BOBCAPS Research

### Stock performance







HOLD TP: Rs 4,121 | ¥ 0%

JK CEMENT

Cement

24 January 2024

## Healthy performance but priced in

- Q3 revenue grew 22% YoY to Rs 27.8bn as new grey cement capacities aided 17% volume growth and realisation improved 5%
- EBITDA spiked to Rs 6.1bn with healthy margins of 21.8%, partly supported by Rs 1.2bn inventory adjustment
- TP revised to Rs 4,121 (vs. Rs 3,578) as we roll valuations over to FY26E; maintain HOLD

Milind Raginwar | Shree Kirloskar research@bobcaps.in

Healthy topline growth continues: JKCE reported 22%/8% YoY/QoQ standalone revenue growth to Rs 27.8bn in Q3FY24. Grey cement volumes at 4.2mn tonnes increased 17%/6% YoY/QoQ while realisation improved 5%/4% to Rs 5,164/t. White cement volumes (including putty) grew 10%/3% YoY/QoQ to 0.4mt and realisation was flat YoY but grew 2.5% QoQ to Rs 12,877/t.

Margins double as cost savings continue: Operating costs fell 8% YoY (-3% QoQ) to Rs 4,756/t as raw material-adjusted energy cost dropped 22% (-10% QoQ) to Rs 1,971/t due to reduced pet coke prices. Logistics cost rose 4%/11% YoY/QoQ to Rs 1,290/t owing to added lead distance to service new markets and busy season surcharge. Other expenditure increased 13% YoY (-5% QoQ) to Rs 4.2bn. Fuel cost savings and a Rs 1.2bn inventory adjustment saw EBITDA surge 2.3x YoY to Rs 6.1bn with strong margin gains to 21.8%. EBITDA/t doubled YoY to Rs 1,330/t.

**Expansion plans on track:** JKCE's 1.5mtpa greenfield Ujjain expansion has been commissioned in Q3FY24 and the 2mt greenfield Panna expansion is due by Q2FY25. The company has also announced a 6mt expansion in Central India (3mt grinding unit in Bihar and 1mt each in Panna, Hamirpur & Prayagra) and 3.3mt clinker line II at Panna at a total project cost of ~Rs 28.5bn, with commissioning within 24 months. Further, an 18MW WHRS unit at Karnataka is expected to be commissioned by Q1FY25.

Positives priced in, retain HOLD: We maintain our FY24/FY25 estimates and introduce FY26 forecasts, modelling for an EBITDA/PAT CAGR of 34%/31% over FY23-FY26. Factoring in higher depreciation and interest payment following capex execution, EPS growth is projected to be relatively slower in FY26. Even so, our TP rises to Rs 4,121 (from Rs 3,578) as we roll valuations over to FY26. Our target FY26E EV/EBITDA multiple remains at 13x target EV/EBITDA multiple, premium to its long-term average – to account for both JKCE's healthy growth outlook and balance sheet stress in the capex phase. Maintain HOLD as the positives appear priced in at current valuations.

### **Key changes**

| Target   | Rating |  |
|----------|--------|--|
| <b>A</b> | < ▶    |  |

| Ticker/Price     | JKCE IN/Rs 4,138  |
|------------------|-------------------|
| Market cap       | US\$ 3.9bn        |
| Free float       | 54%               |
| 3M ADV           | US\$ 6.9mn        |
| 52wk high/low    | Rs 4,211/Rs 2,540 |
| Promoter/FPI/DII | 46%/16%/22%       |
|                  |                   |

Source: NSE | Price as of 24 Jan 2024

# **Key financials**

| Y/E 31 Mar              | FY23A  | FY24E    | FY25E    |
|-------------------------|--------|----------|----------|
| Total revenue (Rs mn)   | 87,768 | 1,09,319 | 1,27,032 |
| EBITDA (Rs mn)          | 11,175 | 17,964   | 23,918   |
| Adj. net profit (Rs mn) | 5,626  | 7,999    | 10,887   |
| Adj. EPS (Rs)           | 72.8   | 103.5    | 140.9    |
| Consensus EPS (Rs)      | 72.8   | 107.0    | 134.0    |
| Adj. ROAE (%)           | 12.9   | 16.2     | 18.6     |
| Adj. P/E (x)            | 56.8   | 40.0     | 29.4     |
| EV/EBITDA (x)           | 31.0   | 19.5     | 14.7     |
| Adj. EPS growth (%)     | (26.0) | 42.2     | 36.1     |

Source: Company, Bloomberg, BOBCAPS Research

### Stock performance









Pharmaceuticals

24 January 2024

# Strong margins make up for subdued revenue growth

- Q3 revenue growth a miss at 6% YoY but robust 670bps expansion in gross margin helped mitigate the impact on bottomline
- EBITDA/PAT grew 19%/13% YoY on higher margins in line with consensus
- Our DCF-based TP stands revised to Rs 765 (vs. Rs 620) as we raise FY24-FY26 EPS 4-8%; maintain HOLD as valuations look fair post rally

Saad Shaikh research@bobcaps.in

External business fares well; GPL declines: GLS reported 6% YoY growth in Q3FY24 revenue to Rs 5.7bn, a miss of 5% compared to Bloomberg consensus. The subdued topline growth stemmed from lower sales in its Glenmark Pharma (GPL) business which declined 2% YoY (-23% QoQ), whereas external business reported a healthy 9% YoY (+6% QoQ) uptick. Management highlighted that the slowdown in GPL business is temporary and was mainly on account of a few developed markets (including Japan which had inventory issues), while emerging markets led the growth. The company did not see any decline in volumes for Q3.

CDMO business rebounds; new multi-year contract to begin in FY25: The CDMO business reported strong revenue growth of 27% YoY and 40% QoQ to Rs 355mn on account of recovery in demand. GLS signed a definitive multi-year agreement with an innovator for the supply of APIs, which is scheduled to be commercialised in FY25. In addition, management indicated that multiple discussions are ongoing with companies globally for further business opportunities in the CDMO space.

Better product mix and favourable input costs lift gross margin: GLS's gross margin expanded 670bps YoY to 57.7% due to a better product mix tilted towards the high-margin CDMO business. Input costs too were favourable as well as the Chinese supply chain has improved and shipments are on track. Employee cost, however, was on the higher side at 13% of sales vs. an average of 9% because of incentive disbursement. Management expects costs to normalise from Q1FY25 onwards. EBITDA margin increased 320bps YoY to 30.1%, supporting EBITDA/PAT growth of 19%/13% YoY to Rs 1.7bn/Rs 1.2bn for the quarter.

**Fully valued; maintain HOLD:** We raise our FY24 earnings estimate by 6% to reflect the sharp uptick in gross and EBITDA margins and our expectations of a similar trend in Q4FY24. We also raise FY25/FY26 earnings by 8%/4% to factor in the new CDMO contract. Our two-step DCF model yields a revised TP of Rs 765 (from Rs 620), but still offers only 4% upside following the recent stock rally. We thus maintain our HOLD rating.

### **Key changes**

| Target   | Rating |  |
|----------|--------|--|
| <b>A</b> | < ▶    |  |

| Ticker/Price     | GLS IN/Rs 800 |
|------------------|---------------|
| Market cap       | US\$ 1.2bn    |
| Free float       | 17%           |
| 3M ADV           | US\$ 1.3mn    |
| 52wk high/low    | Rs 808/Rs 370 |
| Promoter/FPI/DII | 83%/5%/1%     |

Source: NSE | Price as of 24 Jan 2024

#### **Key financials**

| Y/E 31 Mar              | FY23A  | FY24E  | FY25E  |
|-------------------------|--------|--------|--------|
| Total revenue (Rs mn)   | 21,613 | 24,495 | 27,847 |
| EBITDA (Rs mn)          | 6,424  | 7,638  | 9,098  |
| Adj. net profit (Rs mn) | 4,691  | 5,545  | 6,551  |
| Adj. EPS (Rs)           | 38.3   | 45.3   | 53.5   |
| Consensus EPS (Rs)      | 38.3   | 41.8   | 50.5   |
| Adj. ROAE (%)           | 22.0   | 23.4   | 23.4   |
| Adj. P/E (x)            | 20.9   | 17.7   | 15.0   |
| EV/EBITDA (x)           | 15.5   | 12.3   | 10.3   |
| Adj. EPS growth (%)     | 12.0   | 18.2   | 18.1   |

Source: Company, Bloomberg, BOBCAPS Research

### Stock performance







NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

# **Disclaimer**

Name of the Research Entity: BOB Capital Markets Limited

Registered office Address: 1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051

SEBI Research Analyst Registration No: INH000000040 valid till 03 February 2025

Brand Name: BOBCAPS

Trade Name: www.barodaetrade.com CIN: U65999MH1996GOI098009

Logo:



Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

#### Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%

HOLD - Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

#### Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

#### Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

#### General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.



BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

#### Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

#### Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

#### No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

### Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.